M Dodson Michael
Overview
Explore the profile of M Dodson Michael including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
He R, Wang J, Yu Z, Moyers J, Michael M, Durham T, et al.
J Med Chem
. 2022 Oct;
65(20):13892-13909.
PMID: 36197449
Protein tyrosine phosphatases constitute an important class of drug targets whose potential has been limited by the paucity of drug-like small-molecule inhibitors. We recently described a class of active-site-directed, moderately...
2.
Chen Y, Gleaton J, Yang Y, Dhayalan B, Phillips N, Liu Y, et al.
Proc Natl Acad Sci U S A
. 2021 Jul;
118(30).
PMID: 34290145
Insulin-signaling requires conformational change: whereas the free hormone and its receptor each adopt autoinhibited conformations, their binding leads to structural reorganization. To test the functional coupling between insulin's "hinge opening"...
3.
Swinney M, Cox A, Hawkins E, Xue J, Garhyan P, Stanley J, et al.
J Pharm Sci
. 2020 Dec;
110(3):1418-1426.
PMID: 33321138
Insulin infusion sets worn for more than 4-5 days have been associated with a greater risk of unexplained hyperglycemia, a phenomenon that has been hypothesized to be caused by an...
4.
Garibay D, Lou J, Lee S, Zaborska K, Weissman M, Sloma E, et al.
Cell Rep
. 2018 Apr;
23(4):967-973.
PMID: 29694904
Bariatric surgery, such as vertical sleeve gastrectomy (VSG), causes high rates of type 2 diabetes remission and remarkable increases in postprandial glucagon-like peptide-1 (GLP-1) secretion. GLP-1 plays a critical role...
5.
Briere D, Bueno A, Gunn E, Michael M, Sloop K
Diabetes
. 2017 Dec;
67(2):309-320.
PMID: 29203510
Therapeutic engineering of glucagon-like peptide 1 (GLP-1) has enabled development of new medicines to treat type 2 diabetes. These injectable analogs achieve robust glycemic control by increasing concentrations of "GLP-1...
6.
Droz B, Sneed B, Jackson C, Zimmerman K, Michael M, Emmerson P, et al.
PLoS One
. 2017 Jun;
12(6):e0179808.
PMID: 28640904
Obesity in many current pre-clinical animal models of obesity and diabetes is mediated by monogenic mutations; these are rarely associated with the development of human obesity. A new mouse model,...
7.
Peterson R, Jackson C, Zimmerman K, Alsina-Fernandez J, Michael M, Emmerson P, et al.
PLoS One
. 2017 Jun;
12(6):e0179856.
PMID: 28640857
Conclusion: Male FATZO mice spontaneously develop significant metabolic disease when compared to normal controls while maintaining hyperglycemia in the presence of high leptin levels and hyperinsulinemia. The disease condition responds...
8.
Moyers J, Volk C, Cao J, Zhang C, Ding L, Kiselyov V, et al.
Mol Cell Endocrinol
. 2017 Jun;
454:23-38.
PMID: 28576743
Background: Basal insulin peglispro (BIL) is a novel, PEGylated insulin lispro that has a large hydrodynamic size compared with insulin lispro. It has a prolonged duration of action, which is...
9.
Byrd R, Owens R, Blackbourne J, Coutant D, Farmen M, Michael M, et al.
Regul Toxicol Pharmacol
. 2017 May;
88:56-65.
PMID: 28526658
Basaglar/Abasaglar (Lilly insulin glargine [LY IGlar]) is a long-acting human insulin analogue drug product granted marketing authorisation as a biosimilar to Lantus (Sanofi insulin glargine [SA IGlar]) by the European...
10.
Knadler M, Nguyen T, Campanale K, de Veer M, Beals J, Li S, et al.
Pharm Res
. 2016 Aug;
33(12):2920-2929.
PMID: 27528391
Purpose: Determine the pharmacokinetics of insulin peglispro (BIL) in 5/6-nephrectomized rats and study the absorption in lymph duct cannulated (LDC) sheep. Methods: BIL is insulin lispro modified with 20-kDa linear...